Predictive role of peritumoral CD3+ infiltration and neutrophil to lymphocyte ratio on overall survial in pateints affected by colorectal liver metastases treated with chemotherapy and surgery.

Authors

null

Matteo Cimino

Dept. of Hepatobiliary & General Surgery, Humanitas Clinical and Research Center, Humanitas University, Rozzano, Italy

Matteo Cimino, Matteo Donadon, Domenico Mavilio, Luca Di Tommaso, Massimo Roncalli, Kelly Hudspeth, Carlotta Sacerdote, Guido Torzilli

Organizations

Dept. of Hepatobiliary & General Surgery, Humanitas Clinical and Research Center, Humanitas University, Rozzano, Italy, Unit of Clinical and Experimental Immunology, University of Milan, Humanitas Research Hospital, Rozzano, Italy, Department of Pathology, IRCCS Humanitas Clinical Institute and University of Milan School of Medicine, Rozzano, Italy, Department of Pathology Humanitas Cancer Center, Rozzano, Italy, Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in Piemonte, Torino, Italy

Research Funding

Other

Background: Systemic and local inflammation plays an important role in many cancers and colorectal liver metastases (CRLM). While the role of local immune response mediated by CD3+ tumour infiltrating lymphocyte is well established new evidence on systemic inflammation and cancer such as neutrophil–lymphocyte ratio (NLR) are emerging. The aim of the study is to associate these two markers of inflammation to predict overall survival (OS) in patients affected by CRLM. Methods: From January 2006 to January 2013 128 consecutive patients affected by CRLM treated with chemotherapy and surgery were included in the study. CD3+ peritumoral infiltration was defined as the ratio of intra-tumoural\invasive-margin CD3+ infiltration evaluated with immunohistochemistry on CRLM tumor slides. NLR was calculated as neutrophil absolute count divided by the absolute lymphocyte count on blood sample. ROC curves were used to calculate a cut-off for each bio-markers related to OS . Associating the bio-markers two risk groups were determined: low risk (LRG) two protective bio-markers; high risk (HRG) no protective bio-markers. Results: After a median follow-up of 45 months, median OS was 44 months.Twenty-nine patients (22.6%) belong to the LRG whereas 99 patients (77,4) belong to HRG. Adjusted Cox regression analysis showed a worse OS for HRG patients (HR 2.74 p = 0.003 95%CI 1.40-5.37). Median OS was 80.8 vs 42.5 months for LRG vs HRG respectively. Conclusions: High CD3+ peritumoural infiltration associated with low NRL are two protective factor on OS for patients affected by CRLM.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies

Sub Track

Biomarkers and Inflammatory Signatures

Citation

J Clin Oncol 36, 2018 (suppl 5S; abstr 27)

DOI

10.1200/JCO.2018.36.5_suppl.27

Abstract #

27

Poster Bd #

C4

Abstract Disclosures